"OncoView" selected as part of the France 2030 program to drive digital health AI innovation to fight cancer
French Medtech Gleamer invests €18m in its project “OncoView” to fight cancer, and secures significant co-funding from the French government
“OncoView” will be the first comprehensive AI solution designed to assist radiologists in interpreting oncology CT scans.
Gleamer, a global leader in AI for medical imaging, has been chosen by the French government to drive innovation as part of the “Digital Health” initiative.
Paris, December 4, 2024 - Gleamer, a global leader in artificial intelligence applied to medical imaging, has been selected as one of the France 2030 laureates for its groundbreaking project "OncoView". Designed to revolutionize the interpretation of oncology CT scans, OncoView will expand the capabilities of the Gleamer Copilot® by developing an innovative AI solution dedicated to fighting cancer. The project will see a total investment of €18m, including €4.5m co-financed by the French government.
Launched by the government, the France 2030 program is supported by a total budget of €7.5bn to accelerate innovation in key sectors, such as healthcare.
Accelerating innovation in medical imaging
Gleamer’s advancements are driven by close collaboration with leading French healthcare institutions, a network of industrial partners, and an R&D team specializing in AI, data, and clinical research. Through these synergies, Gleamer promotes French technological excellence in artificial intelligence for healthcare on the global stage.
“In ten years, artificial intelligence will be indispensable for interpreting every radiology examination. Studies have confirmed its value: AI boosts both productivity and reliability. Being named a laureate of the France 2030 program is a dual recognition for us - of the strength of our technology, highly acclaimed in France and internationally, and of our pivotal role in shaping the future of radiology. This strategic support will enable us to expand our applications with a new generation of AI solutions specifically dedicated to cancer imaging needs.”, explains Christian Allouche, co-founder and CEO of Gleamer.
“OncoView” tackles cancer diagnosis and monitoring challenges
In 2022, nearly 20 million new cases of cancer were diagnosed, and the global incidence rate is projected to increase by 77% by 2050. Imaging, particularly CT scanning, is a critical pillar in screening, diagnosis, and disease monitoring. In this context, OncoView aims to improve diagnostic accuracy by addressing gaps where a significant number of cancerous lesions remain undetected, while providing reliable and consistent evaluations of treatment outcomes. This personalized approach optimizes care pathways by adapting to the unique needs of each patient.
With an overall investment of €18M over five years, Gleamer is developing a suite of AI applications for the detection, measurement, and monitoring of cancerous lesions, starting with lung and bone lesions, two of the most common metastatic sites.
